Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma

Abstract

Objectives Boron neutron capture therapy (BNCT) is a nuclear reaction-based tumor cell-selective particle irradiation that occurs when nonradioactive Boron-10 is irradiated with low-energy neutrons to produce high-energy α particles (10B [n, α] 7Li). Possible complications associated with extended surgical resection render high-grade meningioma (HGM) a challenging pathology and skull-base meningiomas (SBMs) even more challenging. Lately, we have been trying to control HGMs using BNCT. This study aims to elucidate whether the recurrence and outcome of HGMs and SBMs differ based on their location.

Design Retrospective review.

Setting Osaka Medical College Hospital and Kyoto University Research Reactor Institute.

Participants Between 2005 and 2014, 31 patients with recurrent HGM (7 SBMs) were treated with BNCT.

Main Outcome Measures Overall survival and the subgroup analysis by the anatomical tumor location.

Results Positron emission tomography revealed that HGMs exhibited 3.8 times higher boron accumulation than the normal brain. Although tumors displayed transient increases in size in several cases, all lesions were found to decrease during observation. Furthermore, the median survival time of patients with SBMs post-BNCT and after being diagnosed as high-grade were 24.6 and 67.5 months, respectively (vs non-SBMs: 40.4 and 47.5 months).

Conclusions BNCT could be a robust and beneficial therapeutic modality for patients with high-grade SBMs.

Keywords

boron neutron capture therapy - high-grade meningioma - skull base meningioma - recurrent - boronophenylalanine

• References

• 1 Combs SE, Adeberg S, Dittmar JO. , et al. Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol 2013; 106 (02) 186-191
• 2 Kaul D, Budach V, Misch M, Wiener E, Exner S, Badakhshi H. Meningioma of the skull base: long-term outcome after image-guided stereotactic radiotherapy. Cancer Radiother 2014; 18 (08) 730-735
• 3 Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL. Single-fraction radiosurgery for presumed intracranial meningiomas: efficacy and complications from a 22-year experience. Int J Radiat Oncol Biol Phys 2012; 83 (05) 1414-1418
• 4 Tamura Y, Miyatake S, Nonoguchi N. , et al. Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg 2006; 105 (06) 898-903
• 5 Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 2007; 61 (01) 82-90 , discussion 90–91
• 6 Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S. Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg 2013; 119 (04) 837-844
• 7 Miyatake S, Kawabata S, Hiramatsu R. , et al. Boron neutron capture therapy for malignant brain tumors. Neurol Med Chir (Tokyo) 2016; 56 (07) 361-371
• 8 Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res 1999; 151 (01) 1-18
• 9 Farr LE, Sweet WH, Robertson JS. , et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med 1954; 71 (02) 279-293
• 10 Imahori Y, Ueda S, Ohmori Y. , et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998; 39 (02) 325-333
• 11 Imahori Y, Ueda S, Ohmori Y. , et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res 1998; 4 (08) 1825-1832
• 12 Miyatake S, Kawabata S, Kajimoto Y. , et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 2005; 103 (06) 1000-1009
• 13 Morris GM, Coderre JA, Hopewell JW, Micca PL, Fisher C. Boron neutron capture irradiation of the rat spinal cord: effects of variable doses of borocaptate sodium. Radiother Oncol 1996; 39 (03) 253-259
• 14 Morris GM, Coderre JA, Micca PL, Fisher CD, Capala J, Hopewell JW. Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. Br J Cancer 1997; 76 (12) 1623-1629
• 15 Miyatake S, Kawabata S, Nonoguchi N. , et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro-oncol 2009; 11 (04) 430-436
• 16 Louis DN, Schcithauer BW, Budka H. , et al. Meningiomas. In: Kleihues P, Cavenee WK. , eds. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press; 2000: 176-184
• 17 Louis DN, Ohgaki H, Wiestler OD. , et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
• 18 Sun SQ, Hawasli AH, Huang J, Chicoine MR, Kim AH. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus 2015; 38 (03) E3
• 19 Kaley T, Barani I, Chamberlain M. , et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncol 2014; 16 (06) 829-840
• 20 Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien) 2013; 155 (03) 407-413
• 21 Kane AJ, Sughrue ME, Rutkowski MJ. , et al. Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 2011; 117 (06) 1272-1278
• 22 Sade B, Chahlavi A, Krishnaney A, Nagel S, Choi E, Lee JH. World Health Organization Grades II and III meningiomas are rare in the cranial base and spine. Neurosurgery 2007; 61 (06) 1194-1198 , discussion 1198
• 23 McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 2010; 112 (05) 925-933
• 24 Adeberg S, Hartmann C, Welzel T. , et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 2012; 83 (03) 859-864
• 25 Hakim R, Alexander III E, Loeffler JS. , et al. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery 1998; 42 (03) 446-453 , discussion 453–454
• 26 Ojemann SG, Sneed PK, Larson DA. , et al. Radiosurgery for malignant meningioma: results in 22 patients. J Neurosurg 2000; 93 (Suppl. 03) 62-67
• 27 Stafford SL, Pollock BE, Foote RL. , et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001; 49 (05) 1029-1037 , discussion 1037–1038
• 28 Mizumoto M, Oshiro Y, Tsuboi K. Proton beam therapy for intracranial and skull base tumors. Transl Cancer Res 2013; 2 (02) 87-96
• 29 Boskos C, Feuvret L, Noel G. , et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys 2009; 75 (02) 399-406
• 30 Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS. Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat 2012; 11 (06) 607-614
• 31 Hug EB, Devries A, Thornton AF. , et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 2000; 48 (02) 151-160
• 32 Sakurai Y, Ono K. Improvement of dose distribution by central beam shielding in boron neutron capture therapy. Phys Med Biol 2007; 52 (24) 7409-7422
• 33 Onishi K, Kawabata S, Miyata S. , et al. Evaluation of the biological effects of boron neutron capture therapy for the humanmalignant meningioma cell line IOMM-Lee. Bull Osaka Med Coll 2009; 55 (01) 9-19